Result for
Tag: treatment
September 2, 2020
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-Analysis
A meta-analysis of 7 randomized trials conducted in 12 countries and including 1,703 critically ill patients with COVID-19 found that administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality (OR=0.7, 95%CI 0.5-0.8). Serious adverse events occurred in 64/354 (18%) patients who were randomized to corticosteroids and 80 events…
August 31, 2020
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients
Severe adverse events related to transfusion of convalescent plasma were rare (<1%) among a sample of 20,000 adult patients with severe or life-threatening lab-confirmed COVID-19 who received convalescent plasma treatment. A total of 141(<1%) people experienced serious adverse events (SAEs) related to the transfusion of convalescent plasma within four hours of the procedure and an…
August 28, 2020
Low-Dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants
Catteau et al. conducted a retrospective analysis of in-hospital mortality using Belgian national COVID-19 hospital surveillance data (n=8,075) and found that, after adjusting for clinical and demographic features, mortality was lower among patients who received low-dose hydroxychloroquine (2400 mg over 5 days) compared to supportive care alone (HR=0.7, 95%CI: 0.6-0.8). Catteau et al. (Aug 24,…
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
A retrospective propensity-matched observational study (n=878) found that famotidine, a histamine-2 blocker used to treat acid reflux and ulcers, was associated with a decreased risk of in-hospital mortality (OR=0.4, 95% CI: 0.2-0.96) as well as combined outcome of death or intubation (OR=0.5, 95% CI: 0.2-0.96). While patients treated with famotidine were younger (63.5 +/- 15…
August 26, 2020
Hydroxychloroquine in the Treatment of Outpatients with Mildly Symptomatic COVID-19 A Multi-Center Observational Study
[pre-print, not peer-reviewed] In a retrospective observational study of SARS-CoV-2 infected non-hospitalized patients (n=1,274), hydroxychloroquine exposure was associated with a decreased rate of hospitalization from COVID-19 in a 1,067 patient propensity score matched cohort (OR=0.53, 95%CI 0.29, 0.95). Among outpatients treated with hydroxychloroquine 22% with were hospitalized compared to 32% who did not receive hydroxychloroquine….
August 24, 2020
BCG Vaccination in Infancy Does Not Protect against COVID-19. Evidence from a Natural Experiment in Sweden
By analyzing data from birth cohorts born just before and just after a 1975 policy change that discontinued BCG vaccine in Sweden, de Chaisemartin et al. conclude that the vaccine does not have a protective effect against COVID-19. The authors assessed COVID-19 cases and hospitalizations among 1,026,304 people with the BCG vaccine and 1,018,544 people…
Convalescent Plasma for Patients with Severe COVID-19 a Matched Cohort Study
[pre-print, not peer-reviewed] Rogers et al. found no significant difference in the risk of in-hospital mortality among patients with severe COVID-19 who received convalescent plasma (n=64) and patients with severe COVID-19 (n=177) who did not receive it in an observational study. Although there was no significant difference in the overall rate of hospital discharge, a…
August 21, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial
• An open-label randomized trial of 5- or 10-days of remdesivir treatment compared to standard care found that 5-day remdesivir treatment had a statistically significant improvement in clinical status on day 11 after initiation of treatment, although the clinical importance of the effect was uncertain. The difference in clinical status on day 11 between the…
August 20, 2020
Effectiveness of Remdesivir for the Treatment of Hospitalized Covid-19 Persons
Jiang et al. synthesized results from 4 randomized trials including 2,049 individuals hospitalized with COVID-19 and reported that patients receiving 5-day or 10-day treatment courses with remdesivir had significantly better clinical improvement (OR=1.8 and 1.4, respectively) and higher probabilities of clinical recovery (RR=1.5 and 1.2, respectively) compared to patients receiving placebo. Jiang et al. (Aug…
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
• [Preprint, not peer-reviewed] Walsh et al. report Phase 1 results of an ongoing dose-escalation clinical trial of two RNA vaccine candidates for SARS-CoV-2 (BNT162b1 and BNT162b2) among 195 healthy adults randomized into 13 groups based on age (18-55 or 65-85 years), vaccine type and vaccine dose. Participants received two injections of either vaccine or…
Previous page